双歧杆菌三联活菌散对特应性体质患儿毛细支气管炎后再发喘息的预防作用

目的：观察双歧杆菌三联活菌散对特应性体质患儿毛细支气管炎后再发喘息的预防作用，及对嗜酸性粒细胞（ EOS）和转化生长因子β1（ TGF-β1）水平的影响。方法经监护人知情同意，并签署知情同意书后，采用数字表法将60例毛细支气管炎患儿随机分为治疗组30例，常规治疗组30例，并设健康对照组25例；常规治疗组予毛细支气管炎常规治疗，治疗组予常规治疗外，加用双歧杆菌三联活菌散治疗2个月。于急性期及口服双歧杆菌三联活菌散2月后检测EOS和TGF-β1水平。结果（1）治疗组患儿6月内再次喘息发作次数（0．67±0．13）明显少于常规治疗组（1．27±0．17），差异有统计学意义（P＜0．05）。（2）治疗组和常规治疗组患儿急性期EOS[（0．72±0．13）×109／L和（0．70±0．13）×109／L]均高于健康对照组[（0.16±0．09）×109／L]，差异有统计学意义（P＜0．05）；治疗组和常规治疗组患儿急性期TGF-β1[（1．20±0．13） ng／L和（1.22±0.11） ng／L]均低于健康对照组[（1．45±0．13） ng／L]，差异有统计学意义（P＜0．05）。口服双歧杆菌三联活菌散2月后，治疗组EOS[（0．27±0．12）×109／L]低于常规治疗组[（0．36±0．14）×109／L]，差异有统计学意义（P＜0．05）。治疗组TGF-β1水平[（1．41±0．09） ng／L]高于常规治疗组[（1．34±0．10） ng／L]，差异有统计学意义（P＜0．05）。结论口服双歧杆菌三联活菌散能降低特应性体质毛细支气管炎患儿再发喘息次数并上调患儿EOS和TGF-β1水平。

Effects of live trigeminal bifidobacterium,lactobacillus and enterococcus powder on the recurrence of wheezing in atopic children with bronchiolitis

Objective To observe the effects of live trigeminal bifidobacterium, lactobacillus and enterococcus powder on the recurrence of wheezing, and the levels of peripheral blood eosinophil ( EOS) and serum transforming growth factor-beta 1( TGF-β1) in atopic children with bronchiolitis.Methods Sixty atopic children with bronchiolitis were randomly divided into the therapy group (30 cases) and the conventional treatment group (30 cases) and another 25 healthy children were recruited as the healthy control group. The conventional treatment group was given routine therapy, and the therapy group received live trigeminal bifidobacterium, lactobacil-lus and enterococcus, in addition to routine therapy for 2 months.The levels of EOS and TGF-β1 were detected at the acute stage and 2 months after receiving trigeminal bifidobacterium, lactobacillus and enterococcus.Results (1) The recurrent rate of wheezing after medication for the therapy group (0.67 ±0.13) was significantly lower than that for the conventional treatment group (1.27 ±0.17), with statistical significance (P<0.05).(2)The levels of EOS of the therapy group [(0.72 ±0.13) ×109/L] and the conventional treatment group [(0.70 ±0.13) ×109/L] at the acute stage were markedly higher than those of the healthy control group [(0.16 ± 0.09) ×109/L], also with statistical significance (P<0.05).The levels of TGF-β1 of the therapy group [(1.20 ±0.13) ng/L] and the conventional treatment group(1.22 ±0.11) at acute stage were all considerably lower than those of the control group [(1.45 ± 0.13) ng/L], with statistical significance (P<0.05).The level of EOS in the therapy group [(0.27 ±0.12) ×109/L] 2 months af-ter medication of oral live trigeminal bifidobacterium, lactobacillus and enterococcus powder was lower than that in the conventional treatment group [(0.36 ±0.14) ×109/L], also with statistical significance (P<0.05).The level of TGF-β1 of the therapy group [(1.41 ±0.09) ng/L] 2 months after medication was markedly higher than that of the conventional treatment group [(1.34 ±0.10) ng/L], also with statistical significance (P<0.05).Conclusion Oral medication of live trigeminal bifidobacterium, lactobacillus and enterococcus powder for 2 months could obviously reduce the recurrent rate of wheezing within 6 months after the onset of bronchiolitis and could also up-regulate the levels of EOS and TGF-β1 in atopic children with bronchiolitis.